SELLAS Life Sciences to Showcase Innovative Oncology Treatments
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS), a clinical biopharmaceutical company dedicated to advancing cancer therapies, is preparing to present its latest findings at a prestigious upcoming medical conference. The 66th American Society of Hematology (ASH) Annual Meeting & Exposition is set to take place soon, and SELLAS will highlight the promising results emerging from its Phase 2a trial of SLS009, an innovative CDK9 inhibitor.
Highlights from the Phase 2a Trial
This trial focuses on patients suffering from relapsed/refractory acute myeloid leukemia (r/r AML) who have previously experienced treatment failures with venetoclax. The encouraging results notably include a 50% response rate at the optimal dosing regimen of 30 mg administered twice a week. Furthermore, the safety profile of SLS009 appears robust, with no dose-limiting toxicities reported among the patient population.
Clinical Findings and Patient Outcomes
In the study, the SLS009 treatment revealed significant improvements in median overall survival (OS) compared to standard care regimens. Specifically, a cohort receiving the safety dose of 45 mg weekly exhibited a median OS of 5.5 months versus less than 2.5 months typically seen with standard treatments. Impressively, the higher dose levels of 60 mg and 30 mg BIW have yet to establish a median OS, suggesting further investigation is warranted.
Patient Response and Subgroup Sensitivity
A closer look at the data showcases that 55% of evaluable patients achieved at least a 50% reduction in bone marrow blasts, highlighting the efficacy of SLS009 across varying dosage levels. Notably, those with ASXL1 mutations showed a particularly robust response rate, indicating potential specificity of SLS009, which might engage these tough-to-treat populations effectively. The study emphasizes the importance of confirming the findings through ongoing efforts to explore the medication's impact on patients with AML-myelodysplasia-related changes (AML-MRC).
Details on the ASH Presentation
SELLAS will present these pivotal findings at the ASH Annual Meeting, showcasing their commitment to improving outcomes for patients with challenging hematologic cancers. The presentation details are as follows:
Poster Presentation Information
Title: Phase 2a Study of SLS009, a Highly Selective CDK9 Inhibitor, in Combination with Azacitidine and Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia After Prior Venetoclax Treatment
Session Date and Time: Sunday, December 8, 2024, 6:00 PM - 8:00 PM PST
Session Title: Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II
Location: San Diego Convention Center, Halls G-H
Lead Author: Joshua F. Zeidner, MD, University of North Carolina, Lineberger Comprehensive Cancer Center
Abstract Number: 2877
Understanding SLS009's Role in Cancer Treatment
SLS009 represents a vital part of SELLAS’ innovative plan to tackle a wide variety of cancer types. This CDK9 inhibitor shows exceptional promise within the realm of oncology, especially considering the growing body of evidence suggesting its effectiveness in patients characterized by unfavorable prognostic indicators. As the clinical landscape continues to evolve, therapies like SLS009 could dramatically reshape treatment outcomes.
About SELLAS Life Sciences Group
SELLAS Life Sciences Group is more than just a biopharmaceutical company; it embodies a commitment to patients battling cancer through innovative therapies. Currently spearheading the development of GPS, their lead candidate designed to target the WT1 protein found in many tumor types, SELLAS reinforces its dedication to finding breakthroughs that extend and improve the lives of patients with various malignancies.
Frequently Asked Questions
What is SLS009?
SLS009 is a highly selective CDK9 inhibitor currently being investigated for its therapeutic potential in treating acute myeloid leukemia (AML).
What were the key findings from the Phase 2a trial?
The trial demonstrated a 50% response rate at an optimal dosing level of 30 mg administered twice a week, with significant improvements in median overall survival compared to standard care.
What is the significance of the ASXL1 mutation in this study?
Patients with ASXL1 mutations showed a stronger response to treatment with SLS009, suggesting that the medication may be particularly effective for this subgroup.
When and where will the results be presented?
The results will be presented at the ASH Annual Meeting on December 8, 2024, at the San Diego Convention Center.
How can I learn more about SELLAS Life Sciences?
For more information about the company and its oncology initiatives, visit their official website at www.sellaslifesciences.com.
